Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Snail mucus enriched with carob extract (also known as SSCS) is a natural therapeutic compound under preclinical investigation for inflammatory bowel diseases, particularly ulcerative colitis. [1, 2, 3] It is a biologic/natural product derived from the mucus of snails that have been fed a diet including carob. [1] The active components are believed to be collagen and allantoin from the snail mucus, combined with phenolics, tannins, and flavonoids from the carob extract. [2, 3] The compound has demonstrated anti-inflammatory, antioxidant, and tissue-regenerative properties in preclinical studies. [2] In rat models of ulcerative colitis, the 30% carob-enriched version (SSCS30%) showed protective effects comparable to the drug sulfasalazine, reducing mucosal injury, inflammation, and oxidative stress. [1, 2] Although promising, the compound has not yet been tested in human clinical trials. [1, 3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on snail mucus + carob extract.